top of page
Home
About Us
Platform
Pipeline
GluN2B Antagonism
Patients
Media
Contact
SEYLTX
Pipeline
Disease
Program
Phase 2 Crossover
Phase 2b/3
Approval
Prevalence
Refractory Chronic Cough (RCC)
SEY-101
3,000: 100,000
IPF-CC
SEY-201
13-20: 100,000
Home
About Us
Platform
Pipeline
GluN2B Antagonism
Patients
Media
Contact
Media Center
Careers
Contact
bottom of page